louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04500522: Vaginal Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients
Official title: Vaginal Isonicotinic Acid Hydrazide (INH) Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Infertility, Female
Lead sponsor: Aswan University Hospital
Sponsor class: OTHER
First posted: 2020-08-05
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: double blind randomized controlled trial
Primary purpose: PREVENTION

Brief summary: To compare the effectiveness of vaginal isonicotinic acid hydrazide with placebo in minimizing the pain experienced by primarily infertile patients during diagnostic ofﬁce hysteroscopy and to assess the ease of insertion of hysteroscope as reported by the hysteroscopist.

Detailed description: hysteroscopy is commonly used in the diagnosis and treatment of intrauterine lesions such as polyps, ﬁbroids, septa, and adhesions, and in the presence of abnormal bleeding and during the removal of an intrauterine device or foreign body. Cervical ripening is made possible by the use of medication through different routes.

Eligibility criteria: Inclusion Criteria:

* nulliparous women with primary infertility requiring a diagnostic hysteroscopy as a part of an infertility diagnosis workup

Exclusion Criteria:

* women with suspected pregnancy
* heavy vaginal bleeding
* recent pelvic infection
* those known to have hypersensitivity or contraindication to isonicotinic acid hydrazide
* those who received analgesics prior to office heavy vaginal bleeding
* recent pelvic infection
* a concomitant neurologic disease that could affect the correct evaluation of pain

Primary outcomes:
measure: The difference in pain scores
timeFrame: 10 minutes
Secondary outcomes:
measure: Intensity of pain
timeFrame: 30 minutes after the procedure
measure: Operative time
timeFrame: 15 minutes
Other outcomes:
Locations:
city: Aswan
country: Egypt
facility: Aswan University Hospital
Study officials:
affiliation: Aswan universirty
name: nahla w Shady, md
role: STUDY_CHAIR
References:
Clinical trial NCT06644222: Effectiveness of Airrosti and TheraBand Exercises on Double-Crossed Syndrome in Smart Phone User's Shoulder
Official title: The Effectiveness of Airrosti and TheraBand Exercises on Pain and Disability on Double-Crossed Syndrome in Smart Phone User's Shoulder
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Rounded Shoulder Posture
Keywords: Double crossed syndrom
posture
smart phone users
Lead sponsor: Majmaah University
Sponsor class: OTHER
First posted: 2024-10-16
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two intervention groups
Primary purpose: TREATMENT

Brief summary: Double-crossed syndrome" refers to a specific alignment of overactive and underactive muscles in the neck, chest, and shoulders. AIRROSTI stands for Applied Integration for the Rapid Recovery of Soft Tissue Injuries. This study aims to evaluate the effectiveness of Airrosti exercises combined with TheraBand exercises in reducing pain and disability in the neck and shoulders. TheraBand exercise programs are commonly used to improve muscle activation. However, research on the effectiveness of AIRROSTI combined with TheraBand exercises for treating Double-Crossed Syndrome among smartphone users is limited, and more evidence is needed to support their effectiveness.

Detailed description: Research objective is to evaluate the effectiveness of Airrosti and Theraband exercises in reducing pain and disability among smartphone users with Double-Crossed Syndrome. To evaluate the combined effect of Airrosti and Theraband exercises in reducing pain and disability among smartphone users with Double-Crossed Syndrome. To compare the effect of Airrosti and Theraband exercises in reducing pain and disability among smartphone users with Double-Crossed Syndrome.

Eligibility criteria: Inclusion Criteria:

young female participants with rounded shoulder postures. Participants aged between 18 and 25 years. No history of shoulder trauma, current shoulder pathology, thoracic scoliosis, and kyphosis deformity.

Exclusion Criteria:

Participants excluded if they received any other form of medical treatment or have thoracic scoliosis or kyphosis deformity.

Primary outcomes:
measure: University of California at Los Angeles Activity Scale
timeFrame: 6 week
Secondary outcomes:
Other outcomes:
measure: Double Square Test
timeFrame: 6week
measure: Numeric Pain rating scale
timeFrame: 6 week
Locations:
city: Al Majma'ah
country: Saudi Arabia
facility: Majmaah University
state: Alriyadh
Study officials:
affiliation: Majmaah University
name: Shahnaz Hasan associate Professor, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04377022: Effect of Aerobic Exercise Training on Balance, Walking Capacity, and Quality of Life in Sub-acute Stroke.
Official title: Effect of Aerobic Exercise Training on Balance, Walking Capacity, and Quality of Life in Sub-acute Stroke.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cerebrovascular Stroke
Cerebrovascular Accident, Acute
Cerebral Stroke
Keywords: Aerobic exercise
Stroke
Walking Capacity
Lead sponsor: Government College University Faisalabad
Sponsor class: OTHER
First posted: 2020-05-06
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Stroke is one of the major cause of morbidity and mortality and the leading cause of disability in adults all around the world. Stroke survivors can suffer several neurological impairments and deficits which have an important impact on patient's quality of life and which increase the costs for health and social services. After stroke, impairments in ADLs and functional status, deterioration in health related quality of life can be seen.

The purpose of this study is to Determine the effect of Aerobic exercise training on Balance, Walking capacity and quality of life in sub-acute stroke.


Eligibility criteria: Inclusion Criteria:

* 18 to 75 years of age.
* Stroke that occurred in the recent 3 months.
* Who can walk independently or by using assistive device.
* Have a minimum Chedoke McMaster Stroke Assessment (CMSA) leg impairment score of 3 but less than 7.

Exclusion Criteria:

* Patients were excluded from the study if they have a stroke that occurs more than 3 months.
* If resting blood pressure more than 160/100 even after taking medications
* Have by-pass surgery in recent 3 months.
* Other musculoskeletal problems which restrict the patient's ability to do aerobic activity.

Primary outcomes:
measure: 6 Minute walk Test:
timeFrame: 5 week
Secondary outcomes:
measure: Berg Balance test and rating scale
timeFrame: 5 week
measure: Stroke Impact scale
timeFrame: 5 week
Other outcomes:
Locations:
city: Faisalabad
country: Pakistan
facility: Bin-Inam Rehabilitation Clinic Faisalabad
state: Punjab
Study officials:
affiliation: Government College University, Faislabad
name: Awais bin Inam, MSOMPT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03144622: 18F-FSPG PET/CT Imaging in Patients With Cancers
Official title: (4S)-4-(3-[18F]Fluoropropyl)-L-glutamate Radiotracer (FSPG) PET/CT for Imaging xC- Transporter Activity in Cancers
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pulmonary Cancer
Breast Neoplasms
Abdominal Cancer
Keywords: (4S)-4-(3-[18F]fluoropropyl-)-L-glutamate
18F-FSPG
PET/CT
system xC-transporter
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2017-05-09
Enrollment: 120
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with clinical diagnosis of NSCLC, breast, and abdominal cancers

Brief summary: This study aims to compare the diagnostic performance of 18F-FDG and 18F-FSPG PET/CT in lung, breast, and abdominal cancers before undergoing therapy. In addition, the role of 18F-FSPG PET/CT in evaluating therapy response and prognosis will also be evaluated.


Eligibility criteria: Inclusion Criteria:

* Patients are given the opportunity to participate in the study if

  1. Age ≥ 20 years old.
  2. Confirmed diagnosis of primary cancer of the following: NSCLC, breast or abdominal cancers
  3. ECOG performance status 0 to 2.
  4. Life expectancy \> 3 months.
  5. Consent to perform additional 18F-FSPG and 18F-FDG PET prior to therapy.
  6. Sexually active subjects agree to use condoms and/or their partners of reproductive potential to use a method of effective birth control during imaging period of 2 weeks.

Exclusion Criteria:

* Patients with any of the following conditions will be excluded

  1. Had received previous treatment (excluding neoadjuvant therapy).
  2. Pregnant or lactating women.
  3. Known malignancy in other organs.
  4. Evaluated by primary care physician as unsuitable.
  5. Known hypersensitivity to the study drug.

Primary outcomes:
measure: Staging ability of 18F-FSPG PET/CT
timeFrame: 3 years
measure: Ability of 18F-FSPG PET/CT in therapy response evaluation and prognosis prediction
timeFrame: 3 years
Secondary outcomes:
measure: Uptake of 18F-FSPG
timeFrame: 3 years
measure: Safety of 18F-FSPG PET/CT
timeFrame: 3 years
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital Department of Nuclear Medicine
name: Mei-Fang Cheng, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05449522: Vitamin D for Critically Traumatic Patients
Official title: Effects of High Doses of Liquid Vitamin D Supplementation on Clinical Outcomes in Critically Traumatic Patients.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Vitamin D Deficiency
Major Trauma
Keywords: Vitamin D
Major Trauma
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2022-07-08
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Trauma has been an important global public health issue. Yet it is the sixth cause of death in Taiwan, trauma brings great negative impact to national productivity since it presents specifically as the leading cause of death for the population aged below 40 years. According to the national databank from Formosa Association for the Surgery of Trauma, mortality rate in critically traumatic patients with injury severity score (ISS) ≥ 25 is as high as 23%. Vitamin D, a pleiotropic hormone, regulates directly functions of most organs and immune system. It has been proven that vitamin D insufficiency or deficiency would deteriorate survival of critically ill patients, while supplementation of high-dose vitamin D ameliorates the clinical outcomes. This study investigates whether multiple high doses of vitamin D supplementation in one week can decrease the mortality and morbidity in critically traumatic patients. The serum levels of calcidiol and PTH will be measured on Day 0, Day 3, Day 10, Day 15, Day 30 and Day 60 before and after vitamin D supplementation.


Eligibility criteria: Inclusion Criteria:

* Major trauma adult (\> 20 years old) with Injury Severity Score equal or higher than 9, who is admitted to ICU

Exclusion Criteria:

Patients with the following conditions:

* Chronic liver disease
* Contraindication to enteral feeds
* Hypercalcemia
* Current use of vitamin D, estrogen, or medications for bone disease
* High risk of hypercalcemia, ex. metastatic cancer, primary hyperparathyroidism, sarcoidosis, multiple myeloma

Primary outcomes:
measure: Mortality
timeFrame: up to 3 months after discharge
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Yin-Yi Han, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05290922: DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening
Official title: The Accuracy of Host DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening: a Multi-center, Double-blind, Parallel Controlled Clinical Trials
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Endometrial Cancer
Cancer Screening
DNA Methylation
Testing Accuracy
Cervical Cytology
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
Collaborators: name: Obstetrics & Gynecology Hospital of Fudan University
name: The Third Xiangya Hospital of Central South University
name: Women's Hospital School Of Medicine Zhejiang University
First posted: 2022-03-22
Enrollment: 7150
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All participants will accept surgeries harvesting endometrial histology.

Brief summary: Based on the previous study of NCT04651738, we performed this trial to further confirm the accuracy of host DNA CDO1 and CELF4 methylation for endometrial cancer screening. This study would provide profound basis for the approval of assay kit of DNA methylation in China for endometrial screening. Four hospitals, including Peking Union Medical College Hospital, would enroll eligible patients in this study. The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation, and the results will compared with the endometrial histological pathology, which is achieved after collection of cervical cytology, by surgeries including hysteroscopy, dilation and curettage, total hysterectomy and others. The methylation testing would be double-blinded in operators and analysts. The study will enroll at least 7150 patients.


Eligibility criteria: Inclusion Criteria:

* With uerine and uterine cervix intact
* Aged 18 years or older
* With accessible histological results of endometrium
* Signed an approved informed consents
* With accessible cervical cytology before harvesting endometrial histology

Exclusion Criteria:

* Not meeting all of the inclusion criteria

Primary outcomes:
measure: Sensitivity of methylation testing
timeFrame: One week
measure: Specificity of methylation testing
timeFrame: One week
Secondary outcomes:
measure: Positive predictive value of methylation testing
timeFrame: One week
measure: Negative predictive value of methylation testing
timeFrame: One week
Other outcomes:
Locations:
city: Beijing
country: China
facility: Lei Li
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital
name: Lei Li, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02269722: Postcath Radial Arterial Clamp Time In the CAth Lab
Official title: A Comparison of Radial Artery Clamp Times in Patients Undergoing Cardiac Catheterization Via a Percutaneous Transradial Approach
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Coronary Artery Disease
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2014-10-21
Enrollment: 564
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators will assess the effect of different times of radial clamp post procedure on radial artery occlusion and bleeding.

Detailed description: The purpose of this study is to determine the safety of shorter radial artery clamp time post cardiac catheterization with respect to achieving hemostasis and the incidence of radial artery occlusion. The investigators hypothesize that shorter radial artery clamp times following cardiac catheterization will achieve similar hemostasis to longer clamp times with a decrease in the incidence of radial artery occlusion.

Eligibility criteria: Inclusion Criteria:

* All patients who require cardiac catheterization via the radial approach for the investigation and treatment of coronary artery disease.
* Patients must have evidence of pre-procedural radial artery patency using Barbeau test.
* Patients must be able to give informed consent

Exclusion Criteria:

* Evidence of pre-procedural radial artery thrombosis
* Inability to give informed consent
* Patient desire not to participate in the study
* Emergent procedures when the delay associated for obtaining informed consent may affect patient outcome

Primary outcomes:
measure: Incidence of radial artery occlusion
timeFrame: 24 hours
Secondary outcomes:
measure: Bleeding
timeFrame: 24 hours
Other outcomes:
Locations:
city: London
country: Canada
facility: London Health Science Center
state: Ontario
Study officials:
affiliation: LHSC
name: Shahar Lavi, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lavi S, Cheema A, Yadegari A, Israeli Z, Levi Y, Wall S, Alemayehu M, Parviz Y, Murariu BD, McPherson T, Syed J, Bagur R. Randomized Trial of Compression Duration After Transradial Cardiac Catheterization and Intervention. J Am Heart Assoc. 2017 Feb 3;6(2):e005029. doi: 10.1161/JAHA.116.005029.
Clinical trial NCT02588222: GRINCH: Groningen Initiative on Reference Intervals in Children
Official title: GRINCH: Groningen Initiative on Reference Intervals in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Inflammatory Bowel Disease
Lead sponsor: University Medical Center Groningen
Sponsor class: OTHER
Collaborators: name: Cisbio Bioassays
First posted: 2015-10-27
Enrollment: 120
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy children, aged 6-18 years old

Brief summary: The purpose of this study is to establish reliable reference intervals for fecal S100A12 in healthy children.

Detailed description: RATIONALE S100A12 (calgranulin C) is a cytoplasmic protein secreted exclusively by activated neutrophils. It can be measured in stools and elevated levels are observed in children with inflammatory bowel disease. The protein is stable in stool samples for up to seven days at room temperature, which allows collection at home and potential delays in transport to the laboratory. S100A12 could be used as a marker to discriminate between pediatric inflammatory and functional gastro-intestinal conditions, and prevent children with a low probability of inflammation from unnecessary endoscopic procedures. Until now a reliable reference interval for healthy children is lacking.

OBJECTIVE To establish reliable reference intervals for fecal S100A12 in healthy children.

TIME FRAME Healthy children will be asked to send in one feces sample anonymously during the inclusion period. The investigators expect that the required 120 samples will be collected before December 2015. There will be no follow up of patients.

Eligibility criteria: Inclusion Criteria healthy volunteers:

* Age: 6-18 years old

Exclusion Criteria:

* Treated for any gastro-intestinal symptoms
* Diarrhea in the last week before the collection of the feces sample
* Fever in the last week before collection of the feces sample
* Use of NSAIDs of Proton pump inhibitors in the last 14 days before collection feces sample.

Primary outcomes:
measure: Levels of Calgranulin C (S100A12) in healthy children
timeFrame: One measurement at baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: University Medical Center Groningen
Study officials:
affiliation: University Medical Center Groningen
name: Patrick van Rheenen, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00592722: A Multi-Centre Clinical Study in Chronic Spinal Cord Injury Patients
Official title: A Multi-Centre Clinical Study in Chronic Spinal Cord Injury Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Spinal Cord Injuries
Lead sponsor: China Spinal Cord Injury Network
Sponsor class: NETWORK
Collaborators: name: The University of Hong Kong
First posted: 2008-01-14
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospital

Brief summary: To establish a solid foundation, e.g. network and a coordinating centre for testing new SCI therapies in forthcoming randomized controlled multi-centre clinical trials following international standards and guidelines


Eligibility criteria: Inclusion Criteria:

1. Male or female adult subjects, 18 to 60 years of age;
2. Have a clinical diagnosis of chronic SCI (defined as a history of ≥ 12 months suffering SCI);
3. The diagnosis of SCI was confirmed by MRI; and
4. Voluntarily signs and dates an Informed Consent Form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to any study-specific procedures

Exclusion Criteria:

1. Severe head injury;
2. Is medically or mentally unstable according to the judgement of the Investigator;
3. History of Multiple Sclerosis or peripheral demyelinating disease;
4. Likely to have experimental therapy;
5. Any criteria, which, in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol

Primary outcomes:
measure: The primary study outcomes will be the subject recruitment rate, the subject drip out rate, the number of missing values and the number of submitted incorrect values
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: First Affiliated Hospital of Fujian Medical University
state: Fujian
city: Beijing
country: China
facility: 301 Orthopedic Hospital
city: Chongqing
country: China
facility: Second Affiliated Hospital of Third Military Medcial University
city: Hualien
country: Taiwan
facility: Buddhist Tzu Chi General Hospital
city: Taichung
country: Taiwan
facility: China Medical University Hospital
Study officials:
affiliation: The University of Hong Kong
name: Wise Young, MD, PhD
role: STUDY_DIRECTOR
References: